Masimo (MASI)
(Delayed Data from NSDQ)
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$139.94 USD
+4.27 (3.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $140.00 +0.06 (0.04%) 7:58 PM ET
2-Buy of 5 2
C Value A Growth B Momentum A VGM
Zacks News
3 Medical Instruments Stocks to Buy Amid Industry Challenges
by Urmimala Biswas
The Zacks Medical - Instruments industry is growing on rising demand for digital health. HOLX, MASI and ITGR are set to gain the most. Yet, ongoing inflation, in the form of rising freight and raw material costs, is disrupting the trend.
Down -16.93% in 4 Weeks, Here's Why Masimo (MASI) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Masimo (MASI) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.
Masimo (MASI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
by Zacks Equity Research
Masimo (MASI) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down
by Zacks Equity Research
Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.
Masimo (MASI) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 4.82% and 1.38%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Fulgent Genetics (FLGT) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Fulgent Genetics, Inc. (FLGT) and Masimo (MASI) have performed compared to their sector so far this year.
ConforMIS (CFMS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of 15.38% and 2.37%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Sight Sciences, Inc. (SGHT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 14.63% and 0.89%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Masimo (MASI) Q1 Earnings Expected to Decline
by Zacks Equity Research
Masimo (MASI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Find Strong Buy Medical Stocks Using the Zacks Rank
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Rank.
Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Masimo and Black Knight have been highlighted as Zacks Bull and Bear of the Day.
Bull of the Day: Masimo Corp. (MASI)
by Bryan Hayes
This stock has benefitted from a resurgence in the health care sector.
3 Reasons to Retain HealthEquity (HQY) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about HealthEquity's (HQY) strength in HSA.
Masimo's (MASI) New FDA Approval to Improve Patient Monitoring
by Zacks Equity Research
Masimo's (MASI) receipt of the FDA's clearance for the Rad-G with Temperature is expected to support clinicians in almost any care scenario.
Intuitive Surgical (ISRG) Gains Following Q1 Earnings Beat
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results reflect healthy demand for procedures, partially offset by unfavorable currency. COVID-19 impacts procedure volume in China.
3 Reasons to Retain Merit Medical (MMSI) Stock in Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about Merit Medical (MMSI) owing to its strong product portfolio.
Is Masimo (MASI) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Masimo (MASI) and Ocuphire Pharma, Inc. (OCUP) have performed compared to their sector so far this year.
QuidelOrtho (QDEL) Reports Solid Preliminary Q1 Revenues
by Zacks Equity Research
QuidelOrtho's (QDEL) revenue growth in the first quarter is likely to have been boosted by continued strength in its non-respiratory product sales.
3 Reasons to Retain Veeva Systems (VEEV) Stock in Your Portfolio
by Zacks Equity Research
Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.
Intuitive Surgical (ISRG) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Intuitive Surgical's (ISRG) first-quarter results likely to reflect solid performance in the Instruments & Accessories segment. However, rising costs may have hurt margins.
Here's Why You Should Hold Teladoc Health (TDOC) Stock Now
by Zacks Equity Research
Teladoc Health (TDOC) remains well-poised for growth on the back of solid revenues, sustained demand for virtual care services and sufficient cash-generating abilities.
Masimo (MASI) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about Masimo's (MASI) slew of product launches.
BD's (BDX) New Launch to Result in Optimal IV Placement
by Zacks Equity Research
BD's (BDX) latest launch is expected to advance its vision of a One-Stick Hospital Stay by improving the first-stick success in IV placements.
What's in Store for Abbott Laboratories (ABT) in Q1 Earnings?
by Zacks Equity Research
Abbott Laboratories' (ABT) Established Pharmaceuticals Division (EPD) and Diabetes arm are boosting business in recent months.